September 8, 2008
Exosome Diagnostics Announces Formation of Its Scientific Advisory Board
NEW YORK, Sept. 8 /PRNewswire/ -- Exosome Diagnostics, Inc. today announced the formation of its scientific advisory board with the appointments of Dennis Brown, Ph.D.; Xandra Breakefield, Ph.D.; and Richard L. Edelson, M.D.
Dr. Brown serves as director of Massachusetts General Hospital's program in membrane biology. He is also associate chief for research affairs of Massachusetts General Hospital's nephrology division and a professor at Harvard Medical School. He is a renowned expert in the study of protein trafficking and cell signaling. Dr. Brown earned his Ph.D. in biology from the University of East Anglia in England.Dr. Breakefield is a professor of neurology at Harvard Medical School and a geneticist in neurology and radiology services at Massachusetts General Hospital, where she directs the laboratory of experimental gene therapy. Her laboratory is actively involved in characterizing the role of exosomes produced by tumor cells in the manipulation of normal tissue to promote tumor expansion and as serum biomarkers to monitor tumor status. Dr. Breakefield earned her Ph.D. from Georgetown University.
Dr. Edelson is director of the Yale Cancer Center and a professor at Yale University School of Medicine. He is recognized for his leadership in the studies of cutaneous T cell lymphoma and its therapeutic management. He has published more than 140 original scientific papers, authored or co-authored more than 70 review articles, book chapters and five books, and holds 20 scientific and therapeutic patents. Dr. Edelson earned his M.D. from Yale University School of Medicine.
"Drs. Brown, Breakefield and Edelson will provide Exosome Diagnostics with invaluable counsel as we move forward with expanded clinical trials and commercial launch of a series of blood based diagnostics that profile genetic mutations," said James McCullough, chairman and chief executive officer.
About Exosome Diagnostics
Exosome Diagnostics is a developer of proprietary genetics-based diagnostic tests with applications in oncology and endocrinology. The company's core technology is based on the discovery that circulating nanovesicles called exosomes contain unique genetic markers and that they can be reliably harvested and used as a diagnostic tool for cancers and metabolic diseases. Exosome Diagnostics' lead program is a blood-based diagnostic test for the management of brain tumor patients. For more information, visit http://www.exosomedx.com/.
Exosome Diagnostics, Inc.
Web site: http://www.exosomedx.com/